The Company was incorporated as `Supriya Lifescience Limited' pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai ("RoC"), upon the conversion of `M/s Supriya Chemicals', a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. the Company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by the RoC.
Major events and milestones of the Company : 2008 - Incorporation of the Company upon its conversion from a partnership firm to a public limited company
2009 - Started production of Ketamine Hydrochloride
2010 - CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate
2011 - IDL granted for Chlorphenamine Maleate
2013 - COFEPRIS and KFDA approval granted
2014 - USFDA approval granted - IDL granted for Brompheniramine Maleate
2015 - EUGMP and EDQM approval granted
2017 - CEP (Certificate of Sustainability) granted for Pheniramine Maleate - Second time USFDA approval granted
2018 - CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride
2020 - Third time USFDA approval
2021 - CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate - NMPA approval granted - Health Canada approval
2022-Supriya Lifescience Limited has informed the Exchange regarding 'Intimation Regarding Captive Solar Project Agreement Signed with Enrich Energy Pvt. Ltd'.
2024 -"Supriya Lifescience Ltd Inaugurates State-of-the-Art Module E Production Block at Lote Parshuram, Maharashtra". -Supriya Lifescience inaugurates Rs 125 crore API production block at Lote Parshuram site.
2025 -Supriya Lifescience honoured with Maharashtra State Export Award for two consecutive years -Supriya Lifescience Secures WHO GMP Certification for Ambernath Facility
|